BPC-157 and connective tissue: what the tendon, ligament and bone literature actually shows

BPC-157 came out of gut research. It is a fifteen–amino acid sequence taken from a protein found in human gastric juice, and the first decade of work on it was about the stomach and intestine. The tendon and ligament literature is a later thread, and a thinner one.

That thread is worth reading carefully, because it is the reason most people searching for this compound have heard of it — and because its limits are not obvious from the abstracts.

Who did the work

Almost all of it traces to Pavel Sikiric's group at the University of Zagreb, directly or through collaborators. One laboratory producing the large majority of a compound's literature is not disqualifying, but it is the single most important thing to know before reading any of it. Independent replication is what turns a consistent set of findings into an established one, and for BPC-157 that replication is sparse.

The partial exception in connective tissue is Chang and colleagues in Taiwan, who examined tendon cell outgrowth, survival and migration in culture alongside a rat model, and reported effects on all three (PMID 21030672). That paper is cited heavily precisely because it is not from Zagreb.

What the studies examined

Four injury models carry most of the connective-tissue work.

Tendon transection. Rat Achilles models, in which the tendon is cut and healing is followed over days to weeks. Outcomes are typically histological — how the collagen is organised — alongside mechanical testing of how much load the repaired tendon carries before it fails.

Tendon-to-bone. Krivic and colleagues detached the Achilles from its insertion in rats and followed reattachment, reporting faster recovery of the junction and a counteracting effect against corticosteroid-impaired healing (PMID 16583442). This is the enthesis — the transition zone where tendon meets bone — and it matters disproportionately, because it is where rotator cuff and ACL repairs fail, and because its natural healing produces a weaker structure than the original.

Ligament. Cerovecki and colleagues examined transected knee ligament in rats under the development code PL 14736, reporting improved healing on histological and functional measures (PMID 20225319).

Muscle and bone. A smaller set of crush, transection and bone-defect models, with the same general pattern of reported findings and the same reliance on one group.

The mechanism, as far as it is characterised

Three things recur across the papers, and they are related rather than separate.

The first is angiogenesis — the growth of new blood vessels. This is the thread that runs through the whole BPC-157 literature, gut included, and it is the one with the most direct bearing on connective tissue. Tendon is poorly vascularised at baseline, so blood supply is often what limits how fast it heals and how good the result is. Work in this area points at VEGF receptor signalling and at the nitric oxide pathway.

The second is cell migration. Fibroblasts and tenocytes have to reach an injury before they can rebuild it, and the Chang paper examined exactly this in culture.

The third is collagen organisation rather than collagen quantity. A repaired tendon can lay down plenty of collagen and still be weak, because the fibres are disordered. Several papers measure mechanical strength rather than tissue volume, which is the more demanding endpoint and the more useful one.

What none of this amounts to is a worked-out mechanism. The receptor BPC-157 acts on has not been identified. That is a substantial gap: a compound with no known target is difficult to study systematically and difficult to predict.

Where the evidence stops

It is animal evidence. The connective-tissue literature is rodent work with supporting cell culture. No controlled human trial has examined BPC-157 for tendon, ligament or bone injury.

There was a clinical programme, and it was not about tendons. Under the code PL 14736 the compound was taken into early-phase trials for inflammatory bowel disease. It did not proceed to approval, and the connective-tissue applications were never the subject of a registration programme.

It is not approved anywhere, for anything. Not by Health Canada, not by the FDA, not by the EMA. In 2023 the FDA placed BPC-157 in the category of bulk substances it considers to carry significant safety risks for pharmacy compounding, which is a formal statement that the agency does not regard it as established. It is also on the World Anti-Doping Agency's prohibited list, which matters to anyone who competes.

Rat tendon is not human tendon. Rodents heal faster than people do, at a different scale, and a transected rat Achilles followed for two weeks is a long way from a degenerative human tendinopathy that developed over years.

What this means for a research question

The literature is most developed where blood supply limits repair — tendon, and the tendon-bone junction especially. It is thinnest in cartilage. If a research question is about enthesis biology, there is more published groundwork on this compound than on most; if it is about anything in a human, there is none.

For the parallel cell-migration literature, see TB-500 for Cardiac Research. The combination of the two is examined in Wolverine Stack vs Glow Blend. Nothing here is medical, dosing, or therapeutic guidance.

BPC-157 is supplied here as BPC-157, and as a component of the Wolverine Stack with TB-500. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Common questions

Is BPC-157 proven to heal tendons? No. It has been examined in rat tendon models by a small number of groups, mostly one. "Examined in animals" and "proven" are separated by controlled human trials that do not exist for this compound.

Why does one laboratory dominate the literature? Sikiric's group identified the sequence and has worked on it since the 1990s. The concentration is historical rather than suspicious, but it does mean most findings share a set of methods and assumptions, and independent replication is the thing to look for when reading.

What is the enthesis and why does it keep coming up? It is the graded transition from tendon to bone. It carries the load between two very different tissues, it is where a lot of surgical repairs fail, and it heals naturally into something mechanically inferior to what was there before — so it is a sensible place to look for a compound that might change healing.

Is it legal to buy in Canada? It is sold here as a research chemical, for laboratory use only. It is not an approved drug in Canada and is not sold for human use.

Selected Research References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. pubmed.ncbi.nlm.nih.gov/21548867
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration. Journal of Applied Physiology. 2011;110(3):774-780. pubmed.ncbi.nlm.nih.gov/21030672
3. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. pubmed.ncbi.nlm.nih.gov/16583442
4. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) Improves Ligament Healing in the Rat. Journal of Orthopaedic Research. 2010;28(9):1155-1161. pubmed.ncbi.nlm.nih.gov/20225319
5. Mikus D, Sikiric P, Seiwerth S, et al. Pentadecapeptide BPC 157 Cream Improves Burn-Wound Healing and Vascular Maturation in Mice. Journal of Burn Care & Research. 2001;22(3):200-205.

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.